Oridion gets FDA approval for breathing monitor and new ventilation index systemOridion Systems, a developer of breathing monitoring solutions, has received an FDA 510(k) clearance for its Capnostream 20 capnography monitor with Integrated Pulmonary Index (IPI). Using IPI, clinicians can quickly and easily assess a patient’s ventilation status and monitor a patient’s changing condition. Oridion’s IPI utilizes sophisticated algorithms to integrate the real time measures and interactions of four complex parameters – end tidal CO2 (EtCO2), respiration rate, pulse rate and SpO2 (oxygen saturation) – into a single index value. The result is displayed on a scale from 1-10, where 10 indicates optimal pulmonary status. Gerry Feldman, President of Oridion said that IPI, “will make sophisticated determinations of pulmonary adequacy far more efficient for the diagnosing clinician. More importantly, it will enable the general floor nurse to confidently decide when to call for help.” Oridion develops proprietary medical devices based on its patented Microstream technology which monitors the carbon dioxide (CO2) in a patient’s breath. Products are used in various clinical environments, including procedural sedation, pain management, operating rooms, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients’ ventilation may be compromised and at risk.